Role of plasma 8-OXO-2’-deoxyguanosine in target organ damage in patients with hypertension and type 2 diabetes

Abstract

Background: The aim of the study was to determine the prognostic value of 8-oxo-2’-deoxyguanosine (8-OHdG) plasma levels for cardiovascular complications (CVC) development in hypertension (HTN) and type 2 diabetes mellitus (T2DM) comorbidity. Material and methods: One hundred fifty-six patients (mean age 61.71 ± 0.87 years) with the combined course of HTN stage II and T2DM (group 1) and 100 non-diabetic patients with HTN stage II (mean age 60.59 ± 0.87 years, group 2) were examined. Lipid, carbohydrate metabolism, plasma insulin, plasma 8-OHdG (by ELISA), blood pressure levels were measured. Observation period was 12 months. Results: Plasma levels of 8-OHdG in the patients’ groups were significantly higher than in the controls (p < 0.001), in the group 1 higher than in group 2 (15.37 ± 0.27 ng/L vs . 14.00 ± 0.29 ng/L, respectively, p = 0.002). Plasma levels of 8-OHdG in group-2 patients who developed cardiovascular complications during observation period were significantly higher than in those without cardiovascular complications (16.47 ± 0.62 ng/L vs. 15.11 ± 0.29 ng/L, respectively, p = 0.046). The ROC analysis made it possible to propose the 8-OHdG plasma level ≥ 15.68 ng/L as an identifier for the cardiovascular complications in patients with studied comorbidity. In group 1, in patients with 8-OHdG plasma level ≥ 15.68 ng/L such cardiovascular risk factors as total cholesterol (TC) (p = 0.034), low density lipoprotein cholesterol (LDL-C) (p = 0.035), systolic blood pressure (p = 0.022), HOMA-IR (p = 0.046) were significantly higher compared with those whose level of this indicator was < 15.68 ng/L. Conclusion: Determination of the plasma 8-OHdG allows not only for assessment of the severity of oxidative stress, but also for determination of the course and prognosis in comorbidity of HTN and T2DM.